Kadcyla

November 5, 2020November 5, 2020

Phase 3 Trial to Compare Enhertu to Kadcyla in HER2-Positive, High Risk Patients

News

Daiichi Sankyo and AstraZeneca are initiating a global Phase 3 trial to compare Enhertu (fam-trastuzumab deruxtecan-nxki) to Kadcyla (ado-trastuzumab emtansine, also called T-DM1) as adjuvant therapy in patients with HER2-positive early breast ... Read more

December 6, 2019

CHMP Favors Kadcyla Approval in EU for Certain HER2-positive Early Breast Cancer Patients

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that Kadcyla (ado-trastuzumab emtansine) be approved as an adjuvant (post-surgery) treatment for certain HER2-positive ... Read more

November 6, 2019

First Patient Dosed in Phase 3 Trial of Tucatinib-Kadcyla Combo for Advanced HER2-Positive Breast Cancer

News

A Phase 3 trial exploring a combination of Seattle Genetics‘ tucatinib plus standard Kadcyla (ado-trastuzumab emtansine) in people with advanced HER2-positive breast cancer has dosed its first participant, the company ... Read more

July 22, 2019

Antibody-Drug Conjugate Shows Efficacy in Heavily Treated Cancers

News

An investigational antibody-drug conjugate made of the HER2-targeting antibody trastuzumab (marketed as Herceptin and others) attached to a kind of chemotherapy compound has demonstrated notable efficacy in heavily treated patients ... Read more

May 10, 2019

Kadcyla Approved in US for Some HER2-positive Early Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has extended the use of Genentech‘s Kadcyla (ado-trastuzumab emtansine) as an adjuvant (post-surgery) treatment for some patients with HER2-positive, early-stage breast cancer, the company announced. ... Read more

February 15, 2019February 18, 2019

Experimental Compound Could Broaden HER2-targeted Approach to BC

News

By targeting small regulatory molecules called microRNAs (miRNAs), researchers were able to reprogram breast cancer cells and render them sensitive to HER2-targeting medicines, such as Herceptin (trastuzumab) and Kadcyla (ado-trastuzumab emtansine), a study ... Read more

May 7, 2018May 7, 2018

Possible Reasons Why Tyverb/Tykerb Fails as Breast Cancer Monotherapy Explored in Study

News

Lapatinib, an approved medicine for advanced breast cancer available under the brand names Tyverb in Europe and Tykerb in the U.S., can sometimes cause breast cancer cells to grow under ... Read more

January 5, 2015January 5, 2015

Genentech Updates Results From Phase III MARIANNE Trial In Advanced HER2-Positive Breast Cancer Patients

News

Genentech, a member of the Roche Group, recently announced the results from their Phase III MARIANNE study. MARIANNE is an international, multicenter, randomized, three-arm study comprising 1,095 patients with advanced HER2-positive ... Read more